Clinical trials: Hypoxic Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).
- Trial name
- NCT02865850
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 118 sites in United States, Argentina and 9 more
- Volunteers
- 369 people
- Sponsor
- Akebia Therapeutics
Physiological Function in Low Oxygen Environment
Rapid Acclimatization to Hypoxia at Altitude
In low oxygen environments, such as altitude, some adults may become ill and suffer from acute mountain sickness. Further, all adults will find that exercising becomes much more difficult when compared with exercise at lower…
- Trial name
- NCT01702025
- Testing
- Aminophylline, Methazolamide, Aminophylline+Methazolamide
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Hypoventilation, Hypoxia
Using Capnography to Reduce Hypoxia During Pediatric Sedation
The investigators hypothesize that the addition of capnography during moderate sedation will improve recognition of hypoventilation and apnea.
- Trial name
- NCT01463527
- Testing
- Nellcor NPB-70 Capnograph
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Yale University
Carcinoma, Non-Small-Cell Lung
Palliative Thoracic Radiotherapy Plus BKM120
This study will test whether a drug called BKM120/buparlisib is a safe and effective treatment when given to lung cancer patients having radiotherapy treatment.
- Trial name
- BKM120 (NCT02128724)
- Testing
- BKM120
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Oxford
Idiopathic Pulmonary Fibrosis, Hypoxemia
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
- Trial name
- NCT02846324
- Testing
- GBT440
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Global Blood Therapeutics